Literature DB >> 30098518

IRF4 in multiple myeloma-Biology, disease and therapeutic target.

Alessandro Agnarelli1, Tim Chevassut2, Erika J Mancini3.   

Abstract

Multiple Myeloma (MM) is an incurable hematologic malignancy characterized by abnormal proliferation of plasma cells. Interferon Regulatory Factor 4 (IRF4), a member of the interferon regulatory family of transcription factors, is central to the genesis of MM. IRF4 is highly expressed in B cells and plasma cells where it plays essential roles in controlling B cell to plasma cell differentiation and immunoglobulin class switching. Overexpression of IRF4 is found in MM patients' derived cells, often as a result of activating mutations or translocations, where it is required for their survival. In this review, we first describe the roles of IRF4 in B cells and plasma cells and then analyse the subversion of the IRF4 transcriptional network in MM. Moreover, we discuss current therapies for MM as well as direct targeting of IRF4 as a potential new therapeutic strategy.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Drug discovery; IRF4; Multiple myeloma; Transcription regulation; Treatment

Mesh:

Substances:

Year:  2018        PMID: 30098518     DOI: 10.1016/j.leukres.2018.07.025

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  21 in total

1.  Che-1/AATF-induced transcriptionally active chromatin promotes cell proliferation in multiple myeloma.

Authors:  Tiziana Bruno; Francesca De Nicola; Giacomo Corleone; Valeria Catena; Frauke Goeman; Matteo Pallocca; Cristina Sorino; Gianluca Bossi; Bruno Amadio; Giovanni Cigliana; Maria Rosaria Ricciardi; Maria Teresa Petrucci; Enrico Pierluigi Spugnini; Alfonso Baldi; Mario Cioce; Giancarlo Cortese; Elisabetta Mattei; Roberta Merola; Umberto Gianelli; Luca Baldini; Francesco Pisani; Svitlana Gumenyuk; Andrea Mengarelli; Katja Höpker; Thomas Benzing; Bruno Vincenzi; Aristide Floridi; Claudio Passananti; Giovanni Blandino; Simona Iezzi; Maurizio Fanciulli
Journal:  Blood Adv       Date:  2020-11-24

2.  Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma.

Authors:  Sarah A Holstein; Fotis Asimakopoulos; Abdel Kareem Azab; Giada Bianchi; Manisha Bhutani; Leslie A Crews; Tom Cupedo; Hannah Giles; Sarah Gooding; Jens Hillengass; Lukas John; Shari Kaiser; Lydia Lee; Kylee Maclachlan; Marcelo C Pasquini; Flavia Pichiorri; Nina Shah; Monica Shokeen; Brian R Shy; Eric L Smith; Raluca Verona; Saad Z Usmani; Philip L McCarthy
Journal:  Transplant Cell Ther       Date:  2022-05-21

Review 3.  Acetyl-CoA Synthetase 2 as a Therapeutic Target in Tumor Metabolism.

Authors:  Mengfang Liu; Na Liu; Jinlei Wang; Shengqiao Fu; Xu Wang; Deyu Chen
Journal:  Cancers (Basel)       Date:  2022-06-12       Impact factor: 6.575

4.  Functionalized Scout Fragments for Site-Specific Covalent Ligand Discovery and Optimization.

Authors:  Vincent M Crowley; Marvin Thielert; Benjamin F Cravatt
Journal:  ACS Cent Sci       Date:  2021-04-05       Impact factor: 18.728

Review 5.  Molecular interactions of IRF4 in B cell development and malignancies.

Authors:  Srinivasan Sundararaj; Marco G Casarotto
Journal:  Biophys Rev       Date:  2021-08-13

Review 6.  Targeted Therapy With Immunoconjugates for Multiple Myeloma.

Authors:  Wassilis S C Bruins; Sonja Zweegman; Tuna Mutis; Niels W C J van de Donk
Journal:  Front Immunol       Date:  2020-06-19       Impact factor: 7.561

Review 7.  Therapeutic Targeting of IRFs: Pathway-Dependence or Structure-Based?

Authors:  Cherrie D Thompson; Bharati Matta; Betsy J Barnes
Journal:  Front Immunol       Date:  2018-11-20       Impact factor: 7.561

8.  Screening and identification of key candidate genes and pathways in myelodysplastic syndrome by bioinformatic analysis.

Authors:  Ying Le
Journal:  PeerJ       Date:  2019-11-29       Impact factor: 2.984

9.  Sensitive intranuclear flow cytometric quantification of IRF4 protein in multiple myeloma and normal human hematopoietic cells.

Authors:  Ashni A Vora; Phoebe K Mondala; Caitlin Costello; A Robert MacLeod; Leslie A Crews
Journal:  STAR Protoc       Date:  2021-05-27

10.  Interferon Regulatory Factor 4 Correlated With Immune Cells Infiltration Could Predict Prognosis for Patients With Lung Adenocarcinoma.

Authors:  Xuanzong Li; Shujun Zhai; Jianbo Zhang; Dai Zhang; Shijiang Wang; Linlin Wang; Jinming Yu
Journal:  Front Oncol       Date:  2021-06-14       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.